Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Canadian EdoxAban (Lixiana®) Registry in Patients With ATrial Fibrillation and/or ATrial Flutter With Confirmed ValvUlar HeaRt DiseasE (CAPTURE)

NCT03488420 is registered in ClinicalTrials.gov with Montreal Heart Institute as lead sponsor.

NCT NCT03488420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03488420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Canadian EdoxAban (Lixiana®) Registry in Patients With ATrial Fibrillation and/or ATrial Flutter With Confirmed ValvUlar HeaRt DiseasE (CAPTURE)
Lead sponsor
Montreal Heart Institute
Phase
Observational
Overall status
Completed
Start date
April 30, 2019
Completion date
April 3, 2025
Enrollment
136 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation and flutter, valvular heart disease